Labetalol S.A.L.F.

Labetalol, the active ingredient in Labetalol S.A.L.F., is a non-selective beta blocker with alpha‑1 blocking activity presented as an injectable solution for intravenous use. It treats hypertensive emergencies, severe hypertension, and can be used in pregnancy‑related hypertension such as preeclampsia.

GNH USA supplies Labetalol S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Labetalol is indicated for conditions affecting the cardiovascular pressure regulation system and is employed in acute hypertension management.

Hypertensive emergency: rapid reduction of dangerously high blood pressure. Severe hypertension: sustained control of markedly elevated blood pressure. Hypertensive crisis: immediate management to prevent end‑organ damage. Preeclampsia: blood pressure control in pregnant patients with severe hypertension.

Labetalol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Nausea or vomiting - Flushing or warmth sensation - Nasal congestion

Serious or Rare Side Effects: - Severe hypotension - Bronchospasm or worsening asthma - Heart block or bradyarrhythmia - Hepatic dysfunction or jaundice - Anaphylactic or severe allergic reactions - Cardiogenic shock

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Monitor blood pressure: adjust infusion rate to avoid excessive drops. Assess cardiac function: avoid in severe bradycardia or advanced heart block. Evaluate respiratory status: use cautiously in patients with asthma or COPD. Review hepatic function: dose may need adjustment in liver impairment. Check for drug interactions: avoid concurrent MAO inhibitors or other potent antihypertensives. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Labetalol can interact with several medications, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Calcium channel blockers (verapamil, diltiazem): additive hypotension. - Other antihypertensives: excessive blood pressure lowering. - Beta‑agonists (e.g., albuterol): antagonism of bronchodilation. - Insulin: may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive efficacy. - Tricyclic antidepressants: additive hypotensive effect. - Digoxin: potential increase in serum levels. - Lithium: increased risk of toxicity. - Anesthetic agents: enhanced cardiovascular depression.